Share This Page
technetium tc-99m succimer - Profile
✉ Email this page to a colleague
What are the generic drug sources for technetium tc-99m succimer and what is the scope of patent protection?
Technetium tc-99m succimer
is the generic ingredient in two branded drugs marketed by Theragnostics and Ge Healthcare, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.Summary for technetium tc-99m succimer
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 2 |
| NDAs: | 2 |
US Patents and Regulatory Information for technetium tc-99m succimer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theragnostics | NEPHROSCAN | technetium tc-99m succimer | POWDER;INTRAVENOUS | 214993-001 | Feb 18, 2022 | RX | Yes | Yes | ⤷ Get Started Free | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| Ge Healthcare | MPI DMSA KIDNEY REAGENT | technetium tc-99m succimer kit | INJECTABLE;INJECTION | 017944-001 | May 18, 1982 | DISCN | Yes | No | ⤷ Get Started Free | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Technetium Tc-99m Succimer: Investment Scenario, Market Dynamics, and Financial Trajectory
Executive Summary
Technetium Tc-99m Succimer (also known as Tc-99m DMSA) is a radiopharmaceutical agent primarily used for renal imaging and detecting certain types of tumors. The compound involves complex nuclear medicine supply chains, centered around the radionuclide technetium-99m, generated from molybdenum-99 (Mo-99) generators. This report evaluates the current market, competitive landscape, regulatory environment, and financial prospects of Tc-99m Succimer, emphasizing the investment implications for pharmaceutical companies, nuclear medicine providers, and investors.
Market Overview
Market Size and Demand
The global nuclear medicine market was valued at approximately USD 4.8 billion in 2022, with diagnostic radiopharmaceuticals constituting around 70% of sales.[1] Tc-99m-based imaging agents account for over 80% of nuclear medicine procedures worldwide.
| Parameter | Value / Estimate | Source |
|---|---|---|
| Global nuclear medicine market (2022) | USD 4.8 billion | [1] |
| Share of diagnostic radiopharmaceuticals | 70% of total market | [1] |
| Technetium-99m radiopharmaceuticals | >80% of all nuclear imaging procedures | [2] |
| Estimated global annual procedures | 30 million procedures | [2], [3] |
Demand for Tc-99m Succimer specifically is driven by its applications in renal scintigraphy and tumor detection, especially in pediatric and nephrology populations.
Key Market Drivers
- Aging Population: Increased prevalence of renal and oncological conditions.
- Medical Infrastructure Expansion: Growing nuclear medicine facilities, especially in Asia-Pacific.
- Regulatory Approvals: Continuing approvals and re-approvals for Tc-99m radiopharmaceuticals.
- Supply Chain Resilience: Efforts to ensure stable Mo-99/Tc-99m supply chain.
Market Constraints and Opportunities
| Constraint | Impact | Opportunities |
|---|---|---|
| Mo-99 supply shortages | Supply disruptions, potential revenue loss | Investment in reactor upgrades or alternative methods (e.g., linear accelerators) |
| Stringent regulatory environment | Longer approval timelines, increased costs | Streamlined approval pathways, orphan or niche indications |
| Short half-life of Tc-99m (6 hours) | Logistics challenges | Development of centralized production facilities |
Supply Chain Dynamics
Production of Tc-99m Succimer
- Radionuclide Source: Technetium-99m is derived from Mo-99, produced predominantly via nuclear reactors using highly enriched uranium (HEU) or low-enriched uranium (LEU).
- Generator Systems: Mo-99 generators supply Tc-99m in hospitals and imaging centers.
- Preparation: Tc-99m Succimer is prepared by adding Tc-99m eluate to a DMSA (dimercaptosuccinic acid) kit, which is then radiolabeled in a controlled environment.
Major Production Facilities
| Facility Type | Countries | Market Share | Notes |
|---|---|---|---|
| Molybdenum-99 Reactor Suppliers | Canada (NRU), Netherlands (HFR), South Africa (Safari-1), Belgium (BR2) | 60-70% combined | Aging infrastructure leads to supply concerns |
| Tc-99m Generator Manufacturers | Covidien/GE, Nordion, IBA (Belgium), Mallinckrodt | Dominant suppliers | Significant OEM market share |
| Alternative Production Methods | Cyclotrons, linear accelerators | Emerging | Under research for regional supply stability |
Supply Chain Challenges
- Aging Reactors: The majority of Mo-99 reactors are over 40 years old, with scheduled closures impacting global supply.
- Non-HEU Production Initiatives: Policies favoring LEU-based Mo-99 production, potentially affecting supply consistency.
- Logistical Complexities: Short half-life necessitates rapid distribution, complicating international logistics.
- Regulatory Barriers: Certification for new production techniques or alternative isotopes faces regulatory hurdles.
Market Dynamics and Competitive Landscape
Major Players in Tc-99m Succimer Market
| Company | Role | Market Share/Notes | Regulatory Status |
|---|---|---|---|
| Pactel (IWK Health) | Commercial production | Leading provider in North America | Approved in multiple regions |
| Otake, Inc. | Manufacturer and distributor | Focused on radiopharmaceutical kits | Regulatory approvals obtained |
| Mallinckrodt Pharmaceuticals | Broad portfolio of radiopharm. | Significant global presence | Various approvals |
| Spectrum Pharmaceuticals (formerly) | Niche radiopharm. producer | Focus on pediatric indications | Approved in US, EU |
| Emerging Competitors | Cyclotron-based providers | Developing regional supply solutions | Still under regulatory review |
Market Segmentation
| Segment | Application Areas | Geographical Focus |
|---|---|---|
| Renal Imaging | Detection of renal scarring, function assessment | North America, Europe, Japan |
| Tumor Imaging | Detection of neuroblastoma, metastases | Asia-Pacific, US |
| Pediatric Applications | Less invasive diagnostic options | Global |
| Research and Development | New radiopharmaceuticals | Academia, biotech firms |
Financial Trajectory Analysis
Revenue and Pricing Trends
| Metric | 2022 Estimate | 2025 Forecast | Notes |
|---|---|---|---|
| Global Tc-99m Radiopharmaceutical Revenue | USD 3.84 billion (80% of nuclear med) | USD 4.2 billion (growth driven by demand) | Incremental growth rate ~7.2% annually (compound) |
| Tc-99m Succimer Market Share | Estimated USD 600 million | USD 750-800 million | Based on prevalence of renal and tumor imaging needs |
| Average Price per Dose | USD 100–150 | USD 130–180 | Prices vary by region and facility scale |
| Patent and Regulatory Status | Generic off-patent; regulatory exclusivity for certain formulations | Stable, with ongoing approval renewals | Cost pressure from generics and biosimilars |
Cost of Goods Sold (COGS) Factors
- Radionuclide Production Cost: Significant due to reactor operation, uranium procurement, and associated safety measures.
- Kit Manufacturing: Economies of scale reduce per-unit cost; manufacturing cost approximately USD 20–30 per kit.
- Distribution and Logistics: Short half-life increases transportation costs, especially internationally.
- Regulatory Compliance: Upfront investments in quality systems, ongoing audits, and clinical validation.
Profitability Potential
| Aspect | Details | Impact |
|---|---|---|
| Market Penetration | Established presence with dense hospital networks | Moderate barriers to entry |
| Price Sensitivity | Highly regulated, with reimbursement driven by insurance policies | Moderate to high influence on margins |
| Supply Chain Stability | Critical for revenue continuity; supply shocks limit sales | High investment requirement for supply chain resilience |
Investment Considerations
Risks
| Risk Type | Description | Mitigation Strategies |
|---|---|---|
| Supply Disruption | Mo-99 shortages, reactor shutdowns | Diversify production methods (e.g., cyclotrons) |
| Regulatory Hurdles | Delays or denials in new approvals | Early engagement with regulators |
| Competitive Pressures | Entry of alternative imaging agents | Innovation in radiopharmaceuticals |
| Price Erosion | Increasing generic competition | Differentiation through quality assurance |
Opportunities
| Sector | Description | Expected Impact |
|---|---|---|
| Reactor Modernization | Upgrading aging Mo-99 reactors | Improved supply stability |
| Alternative Radionuclide Production | Cyclotron-based Tc-99m or other isotopes | Near-term regional supply increases |
| International Expansion | Expanding access in emerging markets | Growth in demand due to increased healthcare infrastructure |
| Regulatory Pathway Optimization | Streamlined approval for niche indications | Faster market access |
Comparative Analysis
| Criterion | Tc-99m Succimer | Alternative Imaging Agents | Comments |
|---|---|---|---|
| Diagnostic Accuracy | High for renal and tumor imaging | Variable, depending on modality | Tc-99m generally preferred for its image quality |
| Availability | Linked to Mo-99 supply chain | C-11, F-18, or PET agents depend on cyclotron supply | Tc-99m more established in clinical practice |
| Cost | Moderate-to-high but decreasing with scale | Variable, often higher for PET agents | Cost-effective for broad application |
| Logistics | Challenging due to short half-life | C-11 has similar constraints; F-18 more stable | Logistics focus remains critical |
Key Takeaways
- Market Stability: The global Tc-99m radiopharmaceutical market is robust but faces supply chain vulnerabilities linked to aging reactors and geopolitical issues.
- Growth Potential: Incremental growth driven by aging populations and expanding nuclear medicine infrastructure offers revenue expansion opportunities.
- Investment Risks: Supply disruptions and regulatory delays pose significant risks, but diversification and technological innovations can mitigate these.
- Pricing Trends: Prices tend to decline gradually due to generic competition and new production methods, emphasizing the importance of operational efficiencies.
- Supply Chain Innovations: Transitioning towards cyclotron-based production and regional supply hubs can enhance supply resilience and market stability.
FAQs
Q1: What are the primary drivers for future growth in Tc-99m Succimer?
A1: Increasing global nuclear medicine utilization, technological innovations in production, and expanding healthcare infrastructure, especially in emerging markets.
Q2: How does the supply chain affect investment in Tc-99m Succimer?
A2: Supply chain disruptions, mainly from aging Mo-99 reactors, impact availability and pricing, making diversification and alternative production a priority for investors.
Q3: Are there regulatory challenges for new Tc-99m formulations?
A3: Yes; approvals require extensive clinical data and validation. Streamlined pathways are emerging but remain complex.
Q4: What competitive advantages can companies pursuing Tc-99m Succimer pursue?
A4: Reliable supply, regulatory expertise, production efficiency, and geographic expansion to serve underserved markets.
Q5: How will technological developments impact the market trajectory?
A5: Advancements such as cyclotron-produced Tc-99m can stabilize supply and reduce costs, potentially transforming the competitive landscape.
References
[1] Frost & Sullivan, "Global Nuclear Medicine Market," 2022.
[2] World Nuclear Association, "Medical Isotopes," 2022.
[3] Society of Nuclear Medicine and Molecular Imaging (SNMMI), "Procedures and Application Data," 2022.
Note: All figures are estimates based on available industry sources; actual market data may differ based on regional variations and emerging trends.
More… ↓
